The Structural Genomics Consortium (SGC)

The SGC catalyses research in new areas of human biology and drug discovery by focusing explicitly on less well-studied areas of the human genome. The SGC accelerates research in these new areas by making all its research output available to the scientific community with no strings attached, and by creating an open collaborative network of scientists in hundreds of universities around the world and in eight global pharmaceutical companies. Together, this network of academic and industry scientists is driving a new scientific and drug discovery ecosystem whose primary aim is to advance science and is less influenced by personal, institutional...

Public-private partnership,structural genomics,open access,open innovation,and pre-competitive drug discovery

The structural genomics consortium (sgc) operates in the Research services industry.

The structural genomics consortium (sgc)'s revenue is 11m - 100m

The structural genomics consortium (sgc) has 51 - 200 employees.